|
|
||||||||
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
REPLY: We thank Martínez-Duncker and Hurtado-López for their comments about our paper on 18F-FDG PET in thyroid nodules with inconclusive cytologic results (1). We agree with them that several other radiopharmaceuticals besides 18F-FDG PET can be considered for evaluation of solitary thyroid nodules. They refer to their recent paper on the use of 99mTc-MIBI for this purpose (2). Like 18F-FDG PET, 99mTc-methoxyisobutylisonitrile (MIBI) was positive in all patients with thyroid cancer (1,2). For 18F-FDG PET, this is in line with data in the literature (3,4). However, several studies in the literature do report false-negative 99mTc-MIBI findings in thyroid cancer (5,6).
Furthermore, their study (2) was designed differently from ours (1). First, 78 of 130 patients (60%) underwent diagnostic fine-needle aspiration biopsy (FNAB). These patients do not require any additional imagingneither 18F-FDG PET nor 99mTc-MIBI. This type of group was not included in our study. The remaining 52 patients (40%) had inconclusive FNAB results (2). This is a relatively large percentage of patients, because inconclusive aspirates typically are reported in up to 20% of cases (7,8). The number of patients in the inconclusive-FNAB group who ultimately had thyroid cancer was also relatively high (18/52, or 35%) (2), whereas approximately 20% is typical (9). In our series, the prevalence of thyroid cancer was 14% (1).
When they separately analyzed the results of 99mTc-MIBI imaging in the 52 patients with inconclusive FNAB results (2), 20 of 52 patients (38%) showed negative findings on 99mTc-MIBI scintigraphy and were diagnosed with benign disease. In our study (1), 18F-FDG PET findings were negative in 25 patients (57%), all of whom had benign thyroid nodules.
In conclusion, 18F-FDG seems to be less prone to accumulation in benign thyroid nodules than is 99mTc-MIBI, thereby allowing better selection of patients with inconclusive FNAB results who require surgical intervention. Furthermore, unlike 18F-FDG PET, the literature contains evidence that false-negative 99mTc-MIBI findings do occur in thyroid cancer. For these reasons, we do not support the recommendation of Martínez-Duncker and Hurtado-López that 99mTc-MIBI scans should be the first study performed in the diagnostic algorithm of patients with thyroid nodules and inconclusive cytologic results to avoid unnecessary thyroid surgery. However, a definite conclusion in favor of either 18F-FDG PET or 99mTc-MIBI can be drawn only in a prospective comparative study with appropriately selected patients, especially in view of the high percentage of inconclusive FNAB results and the high prevalence of thyroid cancer in their series (2).
FOOTNOTES
COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |